Avinash Kant, Ph.D.

Eclipsebio develops first-in-class technologies, analyses, and platforms for the development of tomorrow’s RNA-based and RNA-targeting therapies. With our extensive experience in supporting early-stage basic research to evaluating preclinical vaccines and gene therapies, we provide unparalleled support for obtaining deep insights into RNA and therapeutic biology. We offer our solutions as end-to-end partnerships, including custom assay development, for biopharma and biotech companies and as a la carte services. Our areas of support include: - The optimization and characterization of RNA-based vaccines and therapeutics through our eMERGE platform - Multiomic characterization of small molecule and small oligonucleotide targets - Robust validation of on-target, and the identification of off-target, effects from small molecule and small oligonucleotide drugs - Deep profiling of RNA for groundbreaking discoveries in academic research Contact us today to discover how we can provide you with the insights needed for RNA success.

Tactus is a fast-growing, venture-backed company redefining devices and user experiences by combining the best of modern and traditional interfaces. Tactus Technology is the future of our digital touch. Tactus’ scientific design of TrueWrite Film enhances the user experience of writing by improving indentation, static and dynamic friction, acoustics, durability and stylus tip performance. Tactus Technology’s patented shatter protection also gives you a pen on paper feel. Four layers designed to fortify and optimize your devices.

Vixar offers high performance, cost effective, and reliable visible and near IR optical components and solutions. Our VCSEL based solutions can reduce power consumption in your handheld or body worn device, improve the range or precision of your motion control sensor, or enhance performance of your office peripheral or vehicle/home network.

Eclipsebio develops first-in-class technologies, analyses, and platforms for the development of tomorrow’s RNA-based and RNA-targeting therapies. With our extensive experience in supporting early-stage basic research to evaluating preclinical vaccines and gene therapies, we provide unparalleled support for obtaining deep insights into RNA and therapeutic biology. We offer our solutions as end-to-end partnerships, including custom assay development, for biopharma and biotech companies and as a la carte services. Our areas of support include: - The optimization and characterization of RNA-based vaccines and therapeutics through our eMERGE platform - Multiomic characterization of small molecule and small oligonucleotide targets - Robust validation of on-target, and the identification of off-target, effects from small molecule and small oligonucleotide drugs - Deep profiling of RNA for groundbreaking discoveries in academic research Contact us today to discover how we can provide you with the insights needed for RNA success.

Phoenix Venture Partners LLC (PVP) invests in the convergence of advanced materials, biology and hardware with advanced computation and AI (Convergent Tech). We employ a multi-stage investment strategy, encompassing both seed and venture investment programs, and assist entrepreneurs with recruiting and customer and supply chain business development.

Tactus is a fast-growing, venture-backed company redefining devices and user experiences by combining the best of modern and traditional interfaces. Tactus Technology is the future of our digital touch. Tactus’ scientific design of TrueWrite Film enhances the user experience of writing by improving indentation, static and dynamic friction, acoustics, durability and stylus tip performance. Tactus Technology’s patented shatter protection also gives you a pen on paper feel. Four layers designed to fortify and optimize your devices.

Vixar offers high performance, cost effective, and reliable visible and near IR optical components and solutions. Our VCSEL based solutions can reduce power consumption in your handheld or body worn device, improve the range or precision of your motion control sensor, or enhance performance of your office peripheral or vehicle/home network.

Phoenix Venture Partners LLC (PVP) invests in the convergence of advanced materials, biology and hardware with advanced computation and AI (Convergent Tech). We employ a multi-stage investment strategy, encompassing both seed and venture investment programs, and assist entrepreneurs with recruiting and customer and supply chain business development.